BACKGROUND: To report the clinical course of PML in an apparently immunocompetent patient treated with cidofovir. CASE PRESENTATION: A 35-year-old immunocompetent man who developed progressive hemianopsia, aphasia, and limb weakness underwent repeated MRI scans of the brain, spinal fluid analyses, and brain biopsy. Before diagnosis was established based on brain biopsy, he was consecutively treated with methylprednisolone, acyclovir, ceftriaxone and plasmapheresis, but he deteriorated rapidly suggestive of the immune reconstitution inflammatory syndrome (IRIS). He started to recover two weeks after the initiation of treatment with cidofovir and has had no relapse at 3 1/2 years of follow-up. MRI has shown marked improvement. CONCLUSIONS: PML should be considered in immunocompetent patients with a typical clinical course and MRI findings compatible with PML. Treatment with cidofovir should be considered as early as possible in the disease course.
BACKGROUND: To report the clinical course of PML in an apparently immunocompetent patient treated with cidofovir. CASE PRESENTATION: A 35-year-old immunocompetent man who developed progressive hemianopsia, aphasia, and limb weakness underwent repeated MRI scans of the brain, spinal fluid analyses, and brain biopsy. Before diagnosis was established based on brain biopsy, he was consecutively treated with methylprednisolone, acyclovir, ceftriaxone and plasmapheresis, but he deteriorated rapidly suggestive of the immune reconstitution inflammatory syndrome (IRIS). He started to recover two weeks after the initiation of treatment with cidofovir and has had no relapse at 3 1/2 years of follow-up. MRI has shown marked improvement. CONCLUSIONS:PML should be considered in immunocompetent patients with a typical clinical course and MRI findings compatible with PML. Treatment with cidofovir should be considered as early as possible in the disease course.
Authors: Juan Berenguer; Pilar Miralles; Julio Arrizabalaga; Esteban Ribera; Fernando Dronda; Josu Baraia-Etxaburu; Pere Domingo; Manuel Márquez; Francisco J Rodriguez-Arrondo; Fernando Laguna; Rafael Rubio; José Lacruz Rodrigo; J Mallolas; Verónica de Miguel Journal: Clin Infect Dis Date: 2003-04-02 Impact factor: 9.079
Authors: Cinthia B Drachenberg; John C Papadimitriou; Dean Mann; Hans H Hirsch; Ravinder Wali; Emilio Ramos Journal: Transplantation Date: 2005-07-27 Impact factor: 4.939
Authors: A De Luca; M L Giancola; A Ammassari; S Grisetti; A Cingolani; M G Paglia; A Govoni; R Murri; L Testa; A D Monforte; A Antinori Journal: AIDS Date: 2000-09-29 Impact factor: 4.177
Authors: J F Viallard; E Lazaro; E Ellie; S Eimer; F Camou; O Caubet; M E Lafon; H Fleury; J L Pellegrin Journal: Infection Date: 2007-02 Impact factor: 3.553
Authors: Kenneth R Carson; Daniele Focosi; Eugene O Major; Mario Petrini; Elizabeth A Richey; Dennis P West; Charles L Bennett Journal: Lancet Oncol Date: 2009-08 Impact factor: 41.316
Authors: Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Ludwig Kappos; David Bates; Hans-Peter Hartung; Eva Havrdova; David Miller; Chris H Polman; Mads Ravnborg; Stephen L Hauser; Richard A Rudick; Howard L Weiner; Paul W O'Connor; John King; Ernst Wilhelm Radue; Tarek Yousry; Eugene O Major; David B Clifford Journal: Lancet Neurol Date: 2007-05 Impact factor: 44.182
Authors: P Ripellino; C Comi; M Mula; C Varrasi; A Conconi; A Stecco; D Brustia; N Nasuelli; K Savio; L De Paoli; R Cantello; G Gaidano; F Monaco Journal: BMJ Case Rep Date: 2011-04-15
Authors: Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik Journal: Ann Neurol Date: 2015-07-31 Impact factor: 10.422
Authors: Nicolien M van der Kolk; Peer Arts; Ingeborg W M van Uden; Alexander Hoischen; Frank L van de Veerdonk; Mihai G Netea; Brigit A de Jong Journal: Ann Clin Transl Neurol Date: 2016-01-08 Impact factor: 4.511